Navigation Links
Small Molecule Might Play Big Part in Lung Cancer
Date:7/18/2009

High levels of miR-21 were found in nonsmoking patients; could be target for treatment

SATURDAY, July 18 (HealthDay News) -- Researchers have isolated a small molecule that might play a big part in a form of lung cancer that typically strikes people who have never smoked, opening up the possibilities for new treatments for this deadly malignancy.

The microRNA miR-21 was found particularly elevated in adenocarcinomas that affect never-smokers, especially in individuals who tested positive for mutations in their epidermal growth factor receptor (EGFR) gene. Annually, more than 10 percent of lung cancers strike people who never touched a cigarette.

Japanese and American researchers involved in this new study believe that the miR-21 protein is not merely a marker of disease, such as PSA levels are in prostate cancer screenings, but an actual contributor to the cancer process. The findings appear in this week's online issue of the Proceedings of the National Academy of Sciences.

"This is very sophisticated, high-end science," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "It's very intriguing."

Doctors have long known that there are differences in the biology and, ultimately, in the treatment of lung cancers that affect smokers and those that strike people who have never smoked. Among these never-smokers, the most common form of lung cancer is adenocarcinoma, a type of non-small cell cancer that arises in the lungs' peripheral tissues. Non-small cell malignancies make up the majority of U.S. lung cancer cases, followed by small-cell malignancies.

Scientists examined cancer samples from 28 patients, all of them never-smokers who had adenocarcinoma. Compared with tissue samples taken earlier from smokers who had the same disease, miR-21 was noticeably elevated in patients who had never smoked, according to researcher Dr. Curtis Harris, chief of the Laboratory of Human Carcinogenesis at the U.S. National Cancer Institute.

According to Harris, miR-21 is also elevated in tobacco-related adenocarcinoma, but to a lesser extent. Earlier research also showed that elevated levels of miR-21 and other microRNAs were markers for poor survival in smoking-related lung cancer.

All lung cancers are notoriously difficult to treat. They have an overall five-year survival rate of less than 10 percent and kill nearly 160,000 Americans every year. Researchers, therefore, are hopeful whenever they find something in the cancer cell to target with an existing or potential therapy. Two recent targeted therapies for specific lung cancers follow this line of scientific thought -- gefitinib (Iressa) and erlotinib (Tarceva).

To test their hypothesis that miR-21 and EGFR may make attractive targets for therapy, the researchers tested two experimental compounds: an antisense molecule designed to bind to the RNA and essentially turn it off; and a compound called AG1478, which targets the cell's EGFR and tyrosine kinase pathway.

The researchers found that the drugs were most effective in accelerating cancer cell death when used together, suggesting that EGFR plays an important role in miR-21 elevation and cancer creation.

"It's a long road from 'bench to bedside,'" Lichtenfeld said of the findings. "But clearly this study offers the suggestion that there can be an effective treatment for nonsmokers whose adenocarcinoma shows miR-21 elevation."

More information

More on lung cancer can be found at the U.S. National Cancer Institute.



SOURCE: Curtis Harris, M.D., U.S. National Cancer Institute, Bethesda, Md.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; July 13-18, 2009, Proceedings of the National Academy of Sciences, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Anthem Blue Cross and Blue Shield in New Hampshire Gives Boost to Help Small Businesses in the Granite State
2. Fortune Names Mesa Laboratories as one of Americas Fastest Growing Small Public Companies
3. Media invited to ACS Webinar on financing tips for start-ups and small businesses
4. Respiratory Issues Linger for Smallest Babies
5. Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses
6. Drug Crimes in Canada Cause Continuing Problems for Small Communities
7. Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway
8. Finally a Health Care Option for Small Businesses
9. Fortune Recognizes Female Health Company as One of Americas Fastest-Growing Small Companies
10. Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance
11. Children with autism need to be taught in smaller groups, pilot study confirms
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Small Molecule Might Play Big Part in Lung Cancer
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... technology, welcomes you to stop by for a visit this week at HIMSS ... clinicians and executives from around the globe. Sensogram will be featured in the ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Johns Hopkins All ... education building. A topping out ceremony on Friday marked the halfway point of construction ... to open in Fall 2018, will serve as a center for innovation aimed at ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain ... is being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as ... nursing department in early 2016. After a nation-wide search, she was selected to head ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
(Date:2/18/2017)... Beverly Hills, California (PRWEB) , ... February 17, ... ... 273-3007, info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon ... reduce subcutaneous fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Fla. , Feb. 20, 2017 Seal ... its health IT solution for mobile device management and ... 2017 HIMSS Conference and Exhibition in Orlando, ... #4444. Mobile devices have become commonplace in ... comes a new set of concerns, including the disinfection ...
(Date:2/20/2017)... 20, 2017 According to a new market research ... powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End ... The market is projected to reach USD 52.37 Billion by 2021 from ... forecast period. Continue Reading ... ...
(Date:2/19/2017)... 2017   AC Group Inc. , a leading ... vendors in the PMS/EHR healthcare marketplace, will exhibit the ... to succeed in this ecosystem at HIMSS,17. ... obtained from over 200 ACOs, compared and analyzed an ... companies that are providing different pieces of Population Health ...
Breaking Medicine Technology: